Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma.
about
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsCombination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaTargeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibodyHeregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cellsGenetic alterations of HER genes in chromophobe renal cell carcinomaAnti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.Early Detection of Serum Levels of HER-2 in Patients with Head and Neck Squamous Cell Carcinoma.Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.Immunohistochemical Assessment of HER3 Expression in Odontogenic CystsHER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth.Advances in Targeting HER3 as an Anticancer TherapyThe anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.Prognostic significance of HER3 in patients with malignant solid tumors.Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Effects of neratinib and combination with irradiation and chemotherapy in head and neck cancer cells.Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription.Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas.HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma.
P2860
Q26750719-6EEAE41D-1F8F-4DD6-8AB5-9A038747B696Q33875560-61FB794B-FB54-4452-8C66-B785C3A8B1AEQ34036131-9E4AC12C-1B21-44B7-8B4E-431003CA0643Q35193391-9168FB8F-1169-404B-9170-A9076EBB0986Q36117785-E782D8B6-8804-438B-A6EC-E1E9E74729A5Q36356248-7155887A-D7E4-40D7-906F-06FAD8F5E3DDQ36640781-BCD33A1D-CF0F-4E86-A2AE-02E83448C26EQ36670915-6BAE4A7C-A42E-4CA4-8471-9393DE77BC90Q37355106-C9447BBA-BBB3-414D-93E0-2EDF5854399FQ37515219-CFEBB3D4-823D-44FB-909B-21A72B627D28Q38221292-7485590A-5512-401F-9CAD-DB28878D700BQ38382793-2028F80A-E5A9-4DA9-9795-00DBC91F31AAQ38760738-4FD50C28-6B56-47F0-8833-3DC9992CA23CQ38851114-FE402352-C839-4441-A720-751CFF8084F6Q38864254-83140DCC-0F0D-4B37-A203-0E2432D22A47Q41621146-1CB02447-8ADF-42F4-B681-F24FFAFCCCA6Q41667670-FE1220B2-B7AD-4AB6-BBEC-0F9EE508F229Q42120714-4EEE1042-7807-463A-9AD0-5FB21A3BCB6AQ42148898-B5F4371D-305C-46D4-B9CB-B17A585CF8BEQ46738588-3CD6D589-1FAA-4138-BD0B-CF8D40B608B2Q47158524-92F2529A-CB52-418F-8222-9A148BCEEF86Q51603922-E500B20A-0087-479D-9D03-AAB153ABBCC2Q52617485-4CB2D6CB-3583-4F32-B4BA-EE6FC0DF9DFFQ52763519-0D26FCE5-B921-4EE9-AA92-621FC2683B73Q53143666-20F2390D-A395-4C7F-80BD-AFC4CE4F8920Q53799129-2E1B2448-D423-4C77-AF3A-3C3AA7525D0CQ54478596-2D473859-CCEB-4971-B71A-446579C61EE3
P2860
Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Membranous expression of Her3 ...... neck squamous cell carcinoma.
@ast
Membranous expression of Her3 ...... neck squamous cell carcinoma.
@en
type
label
Membranous expression of Her3 ...... neck squamous cell carcinoma.
@ast
Membranous expression of Her3 ...... neck squamous cell carcinoma.
@en
prefLabel
Membranous expression of Her3 ...... neck squamous cell carcinoma.
@ast
Membranous expression of Her3 ...... neck squamous cell carcinoma.
@en
P2093
P2860
P50
P356
P1476
Membranous expression of Her3 ...... neck squamous cell carcinoma.
@en
P2093
Kris Ylaya
Mikiko Takikita
P2860
P2888
P356
10.1186/1479-5876-9-126
P577
2011-07-29T00:00:00Z
P5875
P6179
1049739725